ACS Infectious Diseases,
Год журнала:
2024,
Номер
10(5), С. 1431 - 1457
Опубликована: Апрель 29, 2024
Mucormycosis,
a
rare
but
deadly
fungal
infection,
was
an
epidemic
during
the
COVID-19
pandemic.
The
rise
in
cases
(COVID-19-associated
mucormycosis,
CAM)
is
attributed
to
excessive
steroid
and
antibiotic
use,
poor
hospital
hygiene,
crowded
settings.
Major
contributing
factors
include
diabetes
weakened
immune
systems.
main
manifesting
forms
of
CAM─cutaneous,
pulmonary,
deadliest,
rhinocerebral─and
disseminated
infections
elevated
mortality
rates
85%.
Recent
focus
lies
on
small-molecule
inhibitors
due
their
advantages
over
standard
treatments
like
surgery
liposomal
amphotericin
B
(which
carry
several
long-term
adverse
effects),
offering
potential
central
nervous
system
penetration,
diverse
targets,
simpler
dosing
owing
small
size,
rendering
ability
traverse
blood–brain
barrier
via
passive
diffusion
facilitated
by
phospholipid
membrane.
Adaptation
versatility
mucormycosis
are
multitude
virulence
factors,
enabling
pathogen
dynamically
respond
various
environmental
stressors.
A
comprehensive
understanding
these
mechanisms
imperative
for
devising
effective
therapeutic
interventions
against
this
highly
opportunistic
that
thrives
immunocompromised
individuals
through
its
angio-invasive
nature.
Hence,
Review
delineates
principal
it
employs
persist
challenging
host
environments,
current
progress
developing
them.
Tropical Medicine and Infectious Disease,
Год журнала:
2025,
Номер
10(4), С. 86 - 86
Опубликована: Март 24, 2025
Background/Objectives:
Mucormycosis
is
a
rare
but
life-threatening
fungal
infection,
particularly
in
neonates,
due
to
their
undeveloped
immune
system.
This
systematic
review
aims
analyze
the
risk
factors,
clinical
presentations,
treatments,
and
outcomes
of
neonatal
mucormycosis
reported
between
2004
2024.
Methods:
A
literature
search
was
conducted
PubMed,
Scopus,
Web
Science
following
PRISMA
guidelines.
Only
studies
reporting
cases
neonates
(≤28
days
old)
were
included.
Data
on
features,
diagnostic
methods,
antifungal
therapies,
surgical
interventions,
extracted
analyzed.
Results:
total
44
met
inclusion
criteria,
comprising
61
cases.
The
most
common
presentations
gastrointestinal
(n
=
39),
cutaneous
19),
rhino-orbito-cerebral
2),
disseminated
1).
Diagnosis
primarily
based
histopathology
(93.4%)
culture
(26.2%).
main
treatment
liposomal
amphotericin
B
(63.9%),
often
combined
with
debridement
(60.6%).
Mortality
rates
remained
high
(47.5%),
prematurely
extreme
angioinvasive
disease
or
delayed
diagnosis.
Conclusions:
Neonatal
remains
severe
condition
morbidity
mortality.
Early
diagnosis
through
combination
suspicion
laboratory
confirmation,
along
prompt
therapy
management,
apparently
crucial
for
improving
outcomes.
Further
are
needed
optimize
strategies
improve
survival.
Current Opinion in Infectious Diseases,
Год журнала:
2023,
Номер
36(6), С. 427 - 435
Опубликована: Сен. 21, 2023
Purpose
of
review
Mucormycosis
(MCR)
is
a
common
opportunistic
mold
infection,
and
Mucorales
were
recently
designated
by
WHO
as
priority
pathogens.
The
interest
in
this
infection
has
risen
significantly
since
the
major
outbreak
MCR
context
COVID-19
pandemic,
particularly
India.
Herein,
we
summarize
(last
24
months)
published
information
regarding
clinical
aspects
MCR.
Recent
findings
disease
remains
protean
its
presentation,
difficult
to
diagnose,
challenging
treat.
In
2021,
cases
COVID-19-associated
mucormycosis
(CAM)
exploded
India
during
manifested
primarily
sino-orbital
or
sino-cerebral
disease.
Its
classic
risk
factors
included
triad
COVID-19,
uncontrolled
diabetes
mellitus
use
corticosteroids.
Despite
difficulties
timely
diagnosis
MCR,
significant
progress
been
made
with
molecular
techniques
blood
assist
earlier
diagnosis,
which
can
facilitate
appropriate
therapy
improve
outcomes.
addition,
advances
have
imaging
stage
disease,
determining
what
types
multimodal
are
required
depending
on
staging,
tissue-based
identification
Mucorales.
Summary
Although
outlook
for
improved,
effective
new
antifungals,
stratification,
optimal
multimodality
approaches
remain
an
unmet
need.
Journal of Fungi,
Год журнала:
2024,
Номер
10(1), С. 85 - 85
Опубликована: Янв. 22, 2024
Mucormycosis
presents
a
formidable
challenge
to
clinicians
and
researchers.
Animal
models
are
an
essential
part
of
the
effort
decipher
pathogenesis
mucormycosis
develop
novel
pharmacotherapeutics
against
it.
Diverse
model
systems
have
been
established,
using
range
animal
hosts,
immune
metabolic
perturbations,
infection
routes.
An
understanding
characteristics,
strengths,
drawbacks
these
is
needed
optimize
their
use
for
specific
research
aims.
